Cervical cancer trial underway in Victoria

May 1, 2014 by Susi Hamilton, University of New South Wales
Cervical cancer trial underway in Victoria
HPV virus

As the government considers recommendations for changes to cervical cancer screening, UNSW is already a leading partner in a major trial of the new technology in Victoria.

The new Human Papillomavirus (HPV) testing regime that is being considered involves a five-year test, instead of the current two-yearly Pap . The technology was recently approved in the US and is being piloted in the UK.

"Many women find the experience of screening embarrassing and difficult, so they'll welcome the proposed changes, which would mean the number of tests they undergo over their lives drops from 26 to around 10," says UNSW Associate Professor Canfell, whose group performed the effectiveness and economic modelling that supported the .

If the new testing regime is introduced, it is expected that cervical cancer rates will be reduced by a further 15%, with up to 100 more women a year being spared a cervical cancer diagnosis and up to 30 more lives saved every year.

Compass is the first large-scale clinical trial internationally to compare Pap test screening with HPV screening in an HPV-vaccinated population.

In the first phase, 5,000 Victorian women will be recruited to the trial, which Associate Professor Canfell is co-leading with Associate Professor Marion Saville, Director of the Victorian Cytology Service.

"The Compass trial will give us a pragmatic, real-world experience of HPV testing," says Associate Professor Canfell. "The women who are volunteering for the trial are helping us set up all the systems for testing, if the recommendations are taken up."

"The piloting of a new screening technology involves a lot more than just implementing the in a laboratory," says Associate Professor Marion Saville. "This involves substantial changes to register operations and to information resources. It's very much about how to actually implement a new process of in this country."

The current Compass trial is expected to be rolled out to a larger trial of 100,000 women by the end of the year.

Explore further: Longer screening intervals possible with HPV-based tests

Related Stories

Longer screening intervals possible with HPV-based tests

January 21, 2014
A new study from Karolinska Institutet in Sweden finds that testing for human papilloma virus (HPV) allows for longer time between screening tests when compared to cytology-based testing. The study is published in the scientific ...

Too many Pap tests

July 26, 2013
Most Australian women are currently having more Pap smears than their health requires, according to new research led by a University of New South Wales academic.

FDA experts debate timing of pap test

March 12, 2014
(HealthDay)—The Pap test has been a routine gynecological procedure for generations of American women. But on Wednesday, a Food and Drug Administration advisory panel is considering whether to delay the Pap test and use ...

US OKs first-ever DNA alternative to Pap smear (Update 2)

April 24, 2014
U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

HPV testing could cut cervical cancers by a third

June 14, 2013
(Medical Xpress)—Testing women for the human papillomavirus (HPV) first, instead of using the traditional cervical screening test to detect abnormal cells in the cervix, could prevent around 600 cases of cervical cancer ...

Large-scale HPV self-testing proves effective for screening cervical cancer

January 21, 2014
Self-testing for Human Papillomavirus (HPV) – the virus that causes cervical cancer – is as effective at detecting cancer as a conventional smear test (cytology screening) even when scaled up to test large populations.

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.